Topiramate: Difference between revisions

Revision as of 20:06, 15 June 2021

Revision as of 09:59, 3 August 2021

Line 67:

<!-- Side effects and mechanisms -->

Common side effects include [[paresthesia|tingling]], [[loss of appetite]], feeling tired, abdominal pain, [[hairweight loss]],<ref>{{Cite web|title=Topiramate Side Effects: Common, Severe, Long Term|url=https://www.drugs.com/sfx/topiramate-side-effects.html|access-date=2021-08-03|website=Drugs.com|language=en}}</ref> and decreased cognitive function such as trouble concentrating.<ref name=AHFS2019/><ref name=BNF76>{{cite book|title=British national formulary : BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=9780857113382|pages=328|edition=76}}</ref> Serious side effects may include [[suicide]], increased [[ammonia]] levels resulting in [[encephalopathy]], and [[kidney stones]].<ref name=AHFS2019/> Use in [[pregnancy]] may result in harm to the baby and use during [[breastfeeding]] is not recommended.<ref name=Preg2019>{{cite web |title=Topiramate Pregnancy and Breastfeeding Warnings |url=https://www.drugs.com/pregnancy/pregnancy.html |website=Drugs.com |access-date=3 March 2019 |language=en}}</ref> How it works is unclear.<ref name=AHFS2019/>

<!-- History and culture -->

Line 82:

One common [[off-label use]] for topiramate is in the treatment of [[bipolar disorder]].<ref>{{cite journal |last1=Arnone |first1=D |title=Review of the use of Topiramate for treatment of psychiatric disorders |journal=Annals of General Psychiatry |volume=4 |issue=1 |page=5 |year=2005 |pmid=15845141 |pmc=1088011 |doi=10.1186/1744-859X-4-5}}</ref><ref>{{cite journal|last=Vasudev|first=K|author2=Macritchie, K |author3=Geddes, J |author4=Watson, S |author5= Young, A |editor1-first=Allan H|editor1-last=Young|title=Topiramate for acute affective episodes in bipolar disorder.|journal=The Cochrane Database of Systematic Reviews|date=25 January 2006|issue=1|pages=CD003384|doi=10.1002/14651858.CD003384.pub2|pmid=16437453}}</ref><ref>{{cite journal|last1=Cipriani|first1=A|last2=Barbui|first2=C|last3=Salanti|first3=G|last4=Rendell|first4=J|last5=Brown|first5=R|last6=Stockton|first6=S|last7=Purgato|first7=M|last8=Spineli|first8=LM|last9=Goodwin|first9=GM|last10=Geddes|first10=JR|title=Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis.|journal=Lancet|date=8 October 2011|volume=378|issue=9799|pages=1306–15|pmid=21851976|doi=10.1016/s0140-6736(11)60873-8|s2cid=25512763}}</ref> A review published in 2010 suggested a benefit of topiramate in the treatment of symptoms of [[borderline personality disorder]], however the authors noted that this was based only on one randomized controlled trial and requires replication.<ref>{{cite journal |last1=Leib |first1=Klaus |last2=Völlm |first2=Birgit |last3=Rücker |first3=Gerta |last4=Timmer |first4=Antje |last5=Stoffers |first5=Jutta M |title=Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials |year=2010 |doi=10.1192/bjp.bp.108.062984 |volume=196 |issue=1 |pages=4–12 |journal=British Journal of Psychiatry|pmid=20044651 |doi-access=free }}</ref>

Topiramate has been used as a treatment for [[alcoholism]].<ref>{{cite journal|last=Johnson|first=BA|author2=Ait-Daoud, N |title=Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients.|journal=Current Pharmaceutical Design|date=2010|volume=16|issue=19|pages=2103–12|doi=10.2174/138161210791516404|pmid=20482511|pmc=3063512}}</ref> The VA/DoDVeterans Affairs and the Department of Defense 2015 guideline on substance use disorders lists topiramate as a "strong for" in its recommendations for [[Alcohol Use Disorder|alcohol use disorder]].<ref>{{Cite web|url=https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPGRevised22216.pdf|title=VA/DoD Clinical Practice Guideline for the management of substance use disorders|date=December 31, 2015|website=healthquality.va.gov|access-date=August 30, 2017}}</ref>

Other uses include treatment of obesity,<ref>{{cite journal|vauthors=Verrotti A, Scaparrotta A, Agostinelli S, Di Pillo S, Chiarelli F, Grosso S |title=Topiramate-induced weight loss: a review.|journal=Epilepsy Research|date=August 2011|volume=95|issue=3|pages=189–99|doi=10.1016/j.eplepsyres.2011.05.014|pmid=21684121|s2cid=30103553}}</ref><ref>{{cite journal|last=Kramer|first=CK|author2=Leitão, CB |author3=Pinto, LC |author4=Canani, LH |author5=Azevedo, MJ |author6= Gross, JL |title=Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials.|journal=Obesity Reviews|date=May 2011|volume=12|issue=5|pages=e338–47|doi=10.1111/j.1467-789X.2010.00846.x|pmid=21438989|s2cid=24358798|doi-access=free}}</ref> and [[antipsychoticbinge eating disorder]],<ref>{{Cite web|title=Topiramate for Binge Eating Disorder|url=https://wa.kaiserpermanente.org/kbase/topic.jhtml?docId=ty7109|access-induceddate=2021-08-03|website=wa.kaiserpermanente.org}}</ref> and off-setting weight gain induced by taking [[antipsychotic]] medications.<ref>{{cite journal|last=Hahn|first=MK|author2=Cohn, T |author3=Teo, C |author4= Remington, G |title=Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters.|journal=Clinical Schizophrenia & Related Psychoses|date=January 2013|volume=6|issue=4|pages=186–96|doi=10.3371/CSRP.HACO.01062013|pmid=23302448}}</ref><ref>{{cite journal|last=Mahmood|first=S|author2=Booker, I |author3=Huang, J |author4= Coleman, CI |title=Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents.|journal=Journal of Clinical Psychopharmacology|date=February 2013|volume=33|issue=1|pages=90–4|doi=10.1097/JCP.0b013e31827cb2b7|pmid=23277264|s2cid=26085987}}</ref> In 2012, the combination of [[phentermine/topiramate]] was approved in the United States for weight loss.

It is being studied toas treata potential treatment for [[post traumatic stress disorder]].<ref>{{cite journal|last=Andrus|first=MR|author2=Gilbert, E|date=November 2010|title=Treatment of civilian and combat-related posttraumatic stress disorder with topiramate.|journal=The Annals of Pharmacotherapy|date=November 2010|volume=44|issue=11|pages=1810–6|doi=10.1345/aph.1P163|pmid=20923947|s2cid=12137726}}</ref> In 2012, the combination [[phentermine/topiramate]] was approved in the United States for weight loss.

==Adverse effects==